<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739996</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5357</org_study_id>
    <secondary_id>30005</secondary_id>
    <nct_id>NCT03739996</nct_id>
  </id_info>
  <brief_title>Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1</brief_title>
  <official_title>A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living With HIV-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and
      antiviral activity of long-acting cabotegravir (CAB LA) plus the broadly neutralizing
      monoclonal antibody,VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with
      suppressed plasma viremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the safety, tolerability, pharmacokinetics, and antiviral activity of
      long-acting cabotegravir (CAB LA) plus the broadly neutralizing monoclonal antibody,
      VRC-HIVMAB075-00-AB (VRC07-523LS), in adults living with HIV-1 with suppressed plasma
      viremia.

      The study will be conducted in three steps. At Step 1 entry, all participants will
      discontinue their current antiretroviral therapy (ART) regimen except for nucleoside reverse
      transcriptase inhibitors (NRTIs), and initiate oral CAB.

      During Step 1, participants tolerating oral CAB plus their current two NRTIs, and displaying
      viral suppression (HIV-1 RNA &lt;50 copies/mL), will register to Step 2. At entry into Step 2,
      eligible participants will stop their oral CAB and NRTIs and will receive a VRC07-523LS
      infusion plus CAB LA injection. After entry in Step 2, participants will receive CAB LA every
      4 weeks through Week R2+44 plus VRC07-523LS every 8 weeks through Week R2+40.

      At the last visit in Step 2 (Week R2+48), or at premature study treatment discontinuation,
      all participants who received any CAB LA or VRC07-523LS will enter Step 3 and switch to
      standard of care (SOC) oral ART for approximately 48 weeks.

      Participants will attend a number of study visits throughout the study. Study visits may
      include a physical examination, clinical assessment, pregnancy testing, and blood and urine
      collection. Participants will remain in the study for up to 101 weeks, including
      approximately 5 weeks in Step 1, 48 weeks in Step 2, followed by 48 weeks in Step 3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of either 1) the occurrence of a Grade 3 or higher adverse event (AE); or 2) premature study treatment discontinuation due to an AE (regardless of grade)</measure>
    <time_frame>Measured through Week R2+48 of Step 2</time_frame>
    <description>Both of which are possibly, probably, or definitely related (as judged by the core team) to the CAB LA plus VRC07-523LS combination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience virologic failure</measure>
    <time_frame>Measured through Week R2+44 of Step 2</time_frame>
    <description>Defined as confirmed HIV-1 RNA greater than or equal to 200 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough levels of the concentration of VRC07-523LS</measure>
    <time_frame>Measured through Week R2+48 of Step 2</time_frame>
    <description>Based on PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough levels of the concentration of CAB LA</measure>
    <time_frame>Measured through Week R2+48 of Step 2</time_frame>
    <description>Based on PK sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of viral resistance of breakthrough isolates</measure>
    <time_frame>Measured through Week R2+44 of Step 2</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience virologic failure</measure>
    <time_frame>Measured through Week R2+24 of Step 2</time_frame>
    <description>Defined as confirmed HIV-1 RNA greater than or equal to 200 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of either 1) virologic failure (confirmed HIV-1 RNA greater than or equal to 200 copies/mL); or 2) premature discontinuation of the CAB LA plus VRC07-523LS combination</measure>
    <time_frame>Measured through Week R2+44 of Step 2</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with confirmed HIV-1 RNA greater than or equal to 50 copies/mL</measure>
    <time_frame>Measured through Week R2+44 of Step 2</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with confirmed HIV-1 RNA greater than or equal to 50 copies/mL</measure>
    <time_frame>Measured through Week R2+24 of Step 2</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with either 1) confirmed HIV-1 RNA greater than or equal to 50 copies/mL; or 2) premature discontinuation of the CAB LA plus VRC07-523LS combination</measure>
    <time_frame>Measured through Week R2+44 of Step 2</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience virologic failure</measure>
    <time_frame>Measured through Week R2+44 of Step 2</time_frame>
    <description>Defined by the U.S. Food and Drug Administration (FDA) snapshot algorithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti-idiotype antibodies against VRC07-523LS in samples collected from representative time points throughout the study</measure>
    <time_frame>Measured through Week R2+48 of Step 2</time_frame>
    <description>Based on laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of either 1) the occurrence of a Grade 3 or higher AE; or 2) premature oral CAB discontinuation due to an AE (regardless of grade)</measure>
    <time_frame>Measured through Week 5 of Step 1</time_frame>
    <description>Both of which are possibly, probably, or definitely related (as judged by the core team) to oral CAB.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who prematurely discontinue oral CAB or the CAB LA plus VRC07-523LS combination</measure>
    <time_frame>Measured through Week R2+44 of Step 2</time_frame>
    <description>Based on self report</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of the occurrence of a Grade 3 or higher AE that is possibly, probably, or definitely related (as judged by the core team) to oral CAB or the CAB LA plus VRC07-523LS combination</measure>
    <time_frame>Measured through Week R2+48 of Step 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>CAB LA + VRC07-523LS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.
Step 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.
VRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.
Step 3: SOC oral ART regimen for approximately 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Cabotegravir (CAB)</intervention_name>
    <description>30 mg tablets administered orally</description>
    <arm_group_label>CAB LA + VRC07-523LS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</intervention_name>
    <description>NRTIs will not be provided by the study. Participants will obtain NRTIs outside of the study through routine care.</description>
    <arm_group_label>CAB LA + VRC07-523LS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long-Acting Injectable Cabotegravir (CAB LA)</intervention_name>
    <description>600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection</description>
    <arm_group_label>CAB LA + VRC07-523LS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC07-523LS</intervention_name>
    <description>40 mg/kg administered as an intravenous (IV) infusion</description>
    <arm_group_label>CAB LA + VRC07-523LS</arm_group_label>
    <other_name>VRC-HIVMAB075-00-AB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care (SOC) Oral ART</intervention_name>
    <description>SOC ART will not be provided by the study. Participants will obtain SOC ART outside of the study through routine care.</description>
    <arm_group_label>CAB LA + VRC07-523LS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Step 1 Inclusion Criteria

          -  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or
             chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and
             confirmed by a licensed Western blot or a second antibody test by a method other than
             the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.

               -  NOTE: The term &quot;licensed&quot; refers to a US Food and Drug Administration
                  (FDA)-approved kit, which is required for all IND studies.

               -  World Health Organization (WHO) and Centers for Disease Control and Prevention
                  (CDC) guidelines mandate that confirmation of the initial test result must use a
                  test that is different from the one used for the initial assessment. A reactive
                  initial rapid test should be confirmed by either another type of rapid assay or
                  an E/CIA that is based on a different antigen preparation and/or different test
                  principle (e.g., indirect versus competitive), or a Western blot or a plasma
                  HIV-1 RNA viral load.

          -  Clinically stable (i.e.,in the opinion of the site investigator, doing well and not
             sick from treatment) for at least 8 weeks prior to study entry on a three-drug ART
             regimen that includes a boosted protease inhibitor, a nonnucleoside reverse
             transcriptase inhibitor (NNRTI), or an integrase inhibitor, plus two NRTIs, with no
             history of a switch due to virologic failure.

               -  NOTE: Previous switches for reasons other than virologic failure prior to
                  screening are allowed.

          -  Screening CD4+ T-cell count greater than or equal to 350 cells/mm^3 obtained within 60
             days prior to study entry at any US laboratory that has a Clinical Laboratory
             Improvement Amendments (CLIA) certification or its equivalent.

          -  All available HIV-1 RNA measurements must be less than 50 copies/mL within the 2 years
             prior to study entry except as allowed by the note below.

               -  NOTE: One plasma HIV-1 RNA greater than or equal to 50 copies/mL but less than
                  200 copies/mL is allowed if followed by a subsequent HIV-1 RNA value below 50
                  copies/mL.

          -  Participants must have at least two documented HIV-1 RNA less than 50 copies/mL within
             12 months prior to study entry.

               -  NOTE: The HIV-1 RNA level obtained at the screening visit can be used as the
                  second measurement, but must meet the requirements of screening plasma HIV-1 RNA
                  criterion below.

          -  Screening plasma HIV-1 RNA less than 50 copies/mL by any FDA-approved assay with
             minimum limit of detection of 50 copies/mL or lower obtained within 60 days prior to
             study entry by any US laboratory that has a CLIA certification or its equivalent.

          -  The following laboratory values obtained within 60 days prior to entry at any US
             laboratory that has a CLIA certification or its equivalent.

               -  Absolute neutrophil count (ANC) greater than or equal to 750/mm^3

               -  Hemoglobin greater than or equal to 11.0 g/dL for men or greater than or equal to
                  10.0 g/dL for women

               -  Platelet count greater than or equal to 100,000/mm^3

               -  Calculated creatinine clearance (Cockcroft-Gault formula) greater than or equal
                  to 50 mL/min

               -  Aspartate aminotransferase (AST) (SGOT) less than or equal to 2.0 x ULN

               -  Alanine aminotransferase (ALT) (SGPT) less than or equal to 2.0 x ULN

          -  For females of reproductive potential, negative serum or urine pregnancy test within
             48 hours prior to entry by any clinic or laboratory that has a CLIA certification or
             its equivalent, or is using a point of care (POC)/CLIA-waived test.

               -  NOTE A: Reproductive potential is defined as girls who have reached menarche and
                  women who have had menses within the prior 12 months, and have not undergone
                  surgical sterilization. If no menses for a year or longer, the
                  follicle-stimulating hormone (FSH) should be less than or equal to 40 IU/mL to be
                  considered of reproductive potential. If an FSH is not available, and they have
                  not had menses in 24 or more consecutive months, they would be considered not to
                  be of reproductive potential. Women who have undergone surgical sterilization
                  (e.g., hysterectomy, bilateral oophorectomy, tubal micro-inserts, tubal ligation
                  or salpingectomy) are considered not to be of reproductive potential.

               -  NOTE B: Participant-reported history of hysterectomy and bilateral oophorectomy,
                  tubal ligation, bilateral salpingectomy, tubal micro-inserts, and menopause is
                  acceptable documentation.

               -  Female participants of reproductive potential, who are participating in sexual
                  activity that could lead to pregnancy, must agree to use an effective form of
                  contraception from 30 days prior to the first dose of study medication, while
                  receiving the study drugs, and for 30 days after stopping oral medications, or
                  the duration specified in the product label if receiving ARV drugs not supplied
                  by the study, or for approximately 48 weeks after last dose of CAB LA or
                  VRC07-523LS. Acceptable methods of contraception include:

                    -  Contraceptive subdermal implant

                    -  Intrauterine device or intrauterine system

                    -  Combined estrogen and progestogen oral contraceptive

                    -  Injectable progestogen

                    -  Contraceptive vaginal ring

                    -  Percutaneous contraceptive patches

               -  Women who are not of reproductive potential are eligible to start study treatment
                  drugs without requiring the use of contraceptives. Refer to above criterion for
                  definition of female who is not of reproductive potential.

               -  NOTE: All participants in the study should be counseled on safer sexual practices
                  including the use and benefit/risk of effective barrier methods (e.g., male
                  condom) and on the risk of HIV transmission to a partner without HIV.

          -  Men and women aged greater than or equal to 18 years.

          -  Ability and willingness of participant to provide written informed consent.

          -  Negative HBsAg results obtained within 60 days prior to study entry.

          -  Negative hepatitis C virus (HCV) antibody result obtained within 60 days prior to
             study entry or, if the HCV antibody result is positive, a negative HCV RNA result
             obtained within 60 days prior to study entry.

          -  Susceptibility to VRC07-523LS based on IC50 of less than or equal to 0.25 Âµg/mL and a
             Maximum Percent Inhibition greater than 98% using the Monogram PhenoSense Assay on
             sample obtained at the screening visit.

               -  NOTE: Participants who were in screening as of March 16, 2020 and had their
                  samples drawn for PhenoSense susceptibility testing to VRC07-523LS or completed
                  on or before this date do not need to repeat this testing as part of the
                  re-screening when the study re-opens, provided that there is no documented
                  detectable HIV viral load since the original screen.

          -  Adequate venous access in at least one arm.

          -  Willingness to continue current two NRTIs and expects to have continued access to
             NRTIs in Step 1.

               -  NOTE: NRTIs will not be provided by the study. Participants without continued
                  access to NRTIs will be provided reimbursement for these drugs by the study.

          -  Willingness to not actively engage in the conception process for the duration of the
             study.

        Step 1 Exclusion Criteria

          -  Any previous receipt of humanized or human monoclonal antibody (licensed or
             investigational).

          -  Weight greater than 115 kg or less than 53 kg.

          -  AIDS-defining illness within 60 days prior to study entry.

          -  History of a severe allergic reaction with generalized urticarial, angioedema, or
             anaphylaxis within 2 years prior to study entry.

          -  Currently breastfeeding or pregnant.

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.

          -  Acute or serious illness that, in the opinion of the site investigator, requires
             systemic treatment and/or hospitalization within 60 days prior to entry.

          -  Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine,
             systemic cytotoxic chemotherapy, or investigational therapy within 60 days prior to
             study entry.

               -  NOTE: Participants receiving stable physiologic doses of glucocorticoids, defined
                  as the equivalent of prednisone less than or equal to 10 mg/day, will not be
                  excluded. Stable physiologic glucocorticoid doses should not be discontinued for
                  the duration of the study. In addition, participants receiving inhaled or topical
                  corticosteroids will not be excluded.

          -  Treatment for hepatitis C within 24 weeks prior to study entry.

          -  Vaccinations within 7 days prior to study entry.

               -  NOTE: Participants are encouraged to get routine vaccinations, such as seasonal
                  influenza vaccine outside this window. If vaccination occurs within 7 days prior
                  to study entry, the entry visit should be postponed for at least 7 days after the
                  vaccination.

          -  Initiation of ART during acute HIV-1 infection (as determined by the site investigator
             by history and/or available medical records).

          -  Personal or known family history of prolonged QT syndrome or, in the opinion of the
             site investigator, a clinically significant finding on the screening electrocardiogram
             (ECG) based on an assessment of the screening ECG by that site investigator.

          -  Unstable liver disease (as defined by the presence of ascites, encephalopathy,
             coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice),
             known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic
             gallstones).

          -  Moderate or severe hepatic impairment (Class B or C) as determined by Child-Pugh
             classification.

          -  History of seizures or treatment for seizures within the past 2 years prior to study
             entry.

               -  NOTE: For candidates with a remote (greater than 2 year) history of seizure,
                  consult the A5357 Clinical Management Committee [CMC] for eligibility
                  determination.

        Step 2 Inclusion Criteria

          -  HIV-1 RNA less than 50 copies/mL at week 4 (Step 1), or HIV-1 RNA of 50-199 copies/mL
             at week 4 followed by HIV-1 RNA less than 50 copies/mL at week 5 (Step 1).

          -  Females of reproductive potential must have a negative serum or urine pregnancy test
             obtained within 48 hours prior to Step 2 registration.

               -  NOTE: Refer to the criteria above for definition of reproductive potential and
                  acceptable documentation.

          -  Confirmation that female participant agrees to continue to use an effective form of
             contraception (see criterion above) while on study, and for approximately 48 weeks
             after last dose of CAB LA or VRC07-523LS.

          -  Confirmation of willingness to not actively engage in the conception process for the
             duration of the study.

        Step 2 Exclusion Criteria

          -  Discontinuation or temporary hold of oral CAB for greater than 7 consecutive days for
             any reason during Step 1.

          -  Discontinuation or temporary hold of NRTIs for greater than 7 consecutive days for any
             reason during Step 1.

          -  Grade 3 or 4 adverse event thought to be related to oral CAB during Step 1 according
             to the site investigator.

          -  Vaccination (e.g., influenza) within 7 days prior to the Step 2 registration.

          -  Currently breastfeeding or pregnant.

          -  Any greater than or equal to Grade 2 ALT (greater than 2.5 times ULN) that developed
             during Step 1.

          -  Current implants and/or direct silicone injections on or around the subcutaneous area
             where the study product will be administered.

          -  An overlying tattoo (that is located on or around the skin area where the study
             product will be administered) that, per the site investigator's best clinical
             judgement, would impede clinical care or management in any way.

        Step 3 Inclusion Criterion

          -  Received any CAB LA or VRC07-523LS during Step 2.

               -  NOTE: Participants who prematurely discontinue study treatment for any reason in
                  Step 2 remain eligible for Step 3.

        Step 3 Exclusion Criterion

          -  There are no exclusion criteria to Step 3.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Babafemi Taiwo, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo Tebas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital of the University of Pennsylvania CRS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leah Burke, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Weill Cornell Chelsea CRS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faye Heard, M.P.H.</last_name>
      <phone>205-996-4405</phone>
      <email>fhoward@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleen Khodabakhshian</last_name>
      <phone>310-557-9027</phone>
      <email>akhodabakhshian@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hendrickx, R.N.</last_name>
      <phone>619-543-6968</phone>
      <email>smhendrickx@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ucsf Hiv/Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Dwyer</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>353</phone_ext>
      <email>Jay.Dwyer@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Guerrero</last_name>
      <phone>424-201-3000</phone>
      <phone_ext>7318</phone_ext>
      <email>mguerrero@labiomed.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Fiorillo, M.S.P.H.</last_name>
      <phone>303-724-5931</phone>
      <email>suzanne.fiorillo@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308-2012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ericka Patrick, M.S.N.</last_name>
      <phone>404-616-6313</phone>
      <email>erpatri@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baiba Berzins, M.P.H.</last_name>
      <phone>312-695-5012</phone>
      <email>Baiba@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mall, R.N.</last_name>
      <phone>312-942-5865</phone>
      <email>mark_mall@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Becker, P.A.-C</last_name>
      <phone>410-614-4036</phone>
      <email>rbecke22@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Flynn, R.N., M.S.N., A.N.P., B.S.N.</last_name>
      <phone>617-724-0072</phone>
      <email>tflynn@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl E. Keenan, R.N.</last_name>
      <phone>617-732-5635</phone>
      <email>CKeenan@BWH.Harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael K. Klebert</last_name>
      <phone>314-747-1098</phone>
      <email>mklebert@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School Clinical Research Center CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rondalya DeShields, R.N., B.S.N.</last_name>
      <phone>973-972-3729</phone>
      <email>deshierd@njms.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Chelsea CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Stroberg, R.N., B.S.N.</last_name>
      <phone>212-746-7198</phone>
      <email>tstrober@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Palmer, P.A. -C</last_name>
      <phone>212-342-2958</phone>
      <email>sp500@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Uptown CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fry, M.S.N., FNP</last_name>
      <phone>212-746-4166</phone>
      <email>ref2007@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Straub, B.S.N., M.P.H., R.N.</last_name>
      <phone>919-843-9975</phone>
      <email>bstraub@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Clinical Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kohrs, R.N., B.S.N.</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Watson, B.S.N., R.N.</last_name>
      <phone>614-293-5856</phone>
      <email>kathy.watson@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Therapeutics, CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen B. Donaghy, C.R.N.P.</last_name>
      <phone>215-349-8092</phone>
      <email>eileen.donaghy2@uphs.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn R. Weinman</last_name>
      <phone>412-383-1748</phone>
      <email>drw38@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-9929</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Jonsson, EMBA</last_name>
      <phone>206-744-8886</phone>
      <email>cjonsson@u.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia I. Davila Nieves, M.Sc.</last_name>
      <phone>787-767-9192</phone>
      <email>sylvia.davila1@upr.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.</ipd_time_frame>
    <ipd_access_criteria>With whom?
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses?
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available?
Researchers may submit a request for access to data using the AIDS Clinical Trials Group &quot;Data Request&quot; form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

